dc.contributorUniversidade Federal de São Paulo (UNIFESP)
dc.creatorPelloso, LAF
dc.creatorCampos, MGV de
dc.creatorNascimento, M.
dc.creatorSilva, MRR
dc.creatorPestana, JOM
dc.creatorChauffaille, MDLF
dc.date.accessioned2016-01-24T12:37:43Z
dc.date.accessioned2022-10-07T21:02:57Z
dc.date.available2016-01-24T12:37:43Z
dc.date.available2022-10-07T21:02:57Z
dc.date.created2016-01-24T12:37:43Z
dc.date.issued2005-03-01
dc.identifierLeukemia Research. Oxford: Pergamon-Elsevier B.V., v. 29, n. 3, p. 353-355, 2005.
dc.identifier0145-2126
dc.identifierhttp://repositorio.unifesp.br/handle/11600/28182
dc.identifier10.1016/j.leukres.2004.07.008
dc.identifierWOS:000226957600016
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/4026392
dc.description.abstractImmunosuppressed renal recipients are at an increased risk of developing cancer. Leukemias are less frequent than other hematopoietic tumours and development of CML after immunosuppression is rare. We describe a 37-year-old male who presented with left-shifted leukocytosis, hypercellular bone marrow 32 months after the kidney transplant. G-banding karyotype revealed 46,XY,t(9;22)(q34;q11) and the diagnosis of chronic myeloid leukemia was made. This is the 13th case of CML after kidney transplant reported. Whether this CML appeared as a random phenomenon or chemically induced is a matter of debate. Some individuals might have an increased susceptibility to the effects of azathioprine. (C) 2004 Elsevier B.V. All rights reserved.
dc.languageeng
dc.publisherElsevier B.V.
dc.relationLeukemia Research
dc.rightshttp://www.elsevier.com/about/open-access/open-access-policies/article-posting-policy
dc.rightsAcesso restrito
dc.subjectchronic myeloid leukemia
dc.subjectchemically induced leukemia
dc.subjectkidney transplantation
dc.subjectimmunossupressive drugs
dc.subjectimmunossupression
dc.subjectazathioprine
dc.titleChronic myeloid leukemia following kidney transplantation
dc.typeArtigo


Este ítem pertenece a la siguiente institución